Lv4
484 积分 2022-10-28 加入
PD-L1-armored CD19/CD22 dual-targeted CAR-T cell co-infusion bridging to allogeneic hematopoietic stem cell transplantation achieves 7-year sustained remission in an adult patient with early relapsed, chemorefractory B-cell acute lymphoblastic leukemia: a case report
2个月前
已完结
CAR-neutrophils produced in vivo to treat glioma
2个月前
已完结
CAR-X cell engineering
2个月前
已完结
In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation
3个月前
已完结
T cell-inspired therapeutic delivery platforms: From nanomedicines to cell therapy
4个月前
已关闭
In vivo-generated anti-FAP CAR T cells reduced fibrosis in MASH mice
4个月前
已完结
Synergizing artificial intelligence with in vivo CAR-T cell generation: A new paradigm for democratized immunotherapy
4个月前
已完结
The U.S. Food and Drug Administration’s Perspective on Chimeric Antigen Receptor T-Cell Therapies for Autoimmune and Rheumatic Conditions
5个月前
已完结
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
6个月前
已完结
OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development
7个月前
已完结
皖公网安备34019202002308
